Literature DB >> 3126959

Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

A R Moss1, P Bacchetti, D Osmond, W Krampf, R E Chaisson, D Stites, J Wilber, J P Allain, J Carlson.   

Abstract

The three year actuarial progression rate to the acquired immune deficiency syndrome (AIDS) in a cohort of men in San Francisco who were seropositive for the human immunodeficiency virus (HIV) was 22%. An additional 26 (19%) developed AIDS related conditions. Beta 2 Microglobulin concentration, packed cell volume, HIV p24 antigenaemia, and the proportion and number of T4 lymphocytes each independently predicted progression to AIDS. Beta 2 Microglobulin was the most powerful predictor. The 111 subjects tested who were normal by all predictors (40%) had a three year progression of 7%, and the 68 subjects who were abnormal by two or more predictors (24%) had a progression rate of 57%. Two thirds of all men who progressed to AIDS were in the last group. The median T4 lymphocyte count in subjects who did not progress to AIDS fell from 626 x 10(6) to 327 x 10(6)/l. HIV p24 antigenaemia developed in 7% of the subjects per year. The proportion who were abnormal by two or more predictive variables rose to 41%. At three years an estimated two thirds of the seropositive subjects showed clinical AIDS, an AIDS related condition, or laboratory results that were highly predictive of AIDS. It is concluded from the observed rates and the distribution of predictive variables at three years that half of the men who were seropositive for HIV will develop AIDS by six years after the start of the study, and three quarters will develop AIDS or an AIDS related condition.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Americas; Data Analysis; Developed Countries; Developing Countries; Diseases; Epidemiologic Methods; Estimation Technics; Examinations And Diagnoses; Hiv Infections; Incidence; Measurement; North America; Northern America; Population At Risk; Probability; Research Methodology; Research Report; Statistical Studies; Studies; United States; Viral Diseases

Mesh:

Substances:

Year:  1988        PMID: 3126959      PMCID: PMC2545367          DOI: 10.1136/bmj.296.6624.745

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1985-06-28       Impact factor: 17.586

2.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids.

Authors:  I Berggård; A G Bearn
Journal:  J Biol Chem       Date:  1968-08-10       Impact factor: 5.157

3.  Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-07-03       Impact factor: 17.586

4.  Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome.

Authors:  S Zolla-Pazner; D William; W El-Sadr; M Marmor; R Stahl
Journal:  JAMA       Date:  1984-06-08       Impact factor: 56.272

Review 5.  beta 2-Microglobulin in clinical medicine.

Authors:  F A Karlsson; L Wibell; P E Evrin
Journal:  Scand J Clin Lab Invest Suppl       Date:  1980

6.  Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.

Authors:  D P Stites; C H Casavant; T M McHugh; A R Moss; S L Beal; J L Ziegler; A M Saunders; N L Warner
Journal:  Clin Immunol Immunopathol       Date:  1986-02

7.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age.

Authors:  M E Eyster; M H Gail; J O Ballard; H Al-Mondhiry; J J Goedert
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  The acquired immunodeficiency syndrome in a cohort of homosexual men. A six-year follow-up study.

Authors:  H W Jaffe; W W Darrow; D F Echenberg; P M O'Malley; J P Getchell; V S Kalyanaraman; R H Byers; D P Drennan; E H Braff; J W Curran
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  94 in total

1.  HIV INFECTION IN HERPES ZOSTER.

Authors:  Plk DE Sylva; K M Shah; H Mani; A K Hukkoo; S Bhattacharya; Yogesh Chander
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

Authors:  D R Bainbridge; M W Lowdell; I M Hannet; K W Strauss; A Karpas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-07-29       Impact factor: 6.237

Review 3.  Clinical and immunological assessment of HIV infection.

Authors:  A G Bird
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

4.  CD8 T lymphocyte subset markers and HIV infection.

Authors:  A G Bird; K C Watret
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

5.  Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics.

Authors:  M A Testa; W R Lenderking
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 6.  Infection and infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

Review 7.  Randomised placebo controlled trials in HIV infection: to be or not to be?

Authors:  K Gelmon; I V Weller
Journal:  Genitourin Med       Date:  1989-06

Review 8.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

9.  The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion.

Authors:  C A Sabin; A N Phillips; C A Lee; G Janossy; V Emery; P D Griffiths
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

10.  Planning community-wide services for persons with HIV infection in an area of moderate incidence.

Authors:  S L Lenker; D P Lubeck; A Vosler
Journal:  Public Health Rep       Date:  1993 May-Jun       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.